Sitagliptin-induced hemolysis

Indian Journal of Pharmacology

Volumn 42, Issue 5, 2010, Pages 320-321

  Bekur, Ragini ^a   Nagaraja, M V ^a   Shivashankara, K N ^a   Stanley, Weena ^a  

^a KASTURBA MEDICAL COLLEGE   (India)

Author keywords

Dipeptidyl peptidase inhibitor; hemolysis; sitagliptin

Indexed keywords

HUMAN INSULIN; IRBESARTAN; METFORMIN; RAMIPRIL; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT;

ADD ON THERAPY; ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE REGULATION; BLOOD SMEAR; CASE REPORT; DIABETES CONTROL; DIABETIC PATIENT; DISEASE SEVERITY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HEMOLYSIS; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOGLYCEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER FUNCTION; LUNG EDEMA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PATIENT MONITORING; RETICULOCYTE COUNT; SIDE EFFECT; WEIGHT GAIN;

EID: 77957728007     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.70405     Document Type: Article

References (8)

1. Nathan DM, Davidson MB, De Fronzo RA, Heine RJ, Henry RR, Pratley R, et al. Impaired fasting glucose and impaired glucose tolerance; Implications for care. Diabetes Care 2007;30:753-9.
2. Durbin RJ. Thiazolidinedione therapy in the prevention\delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 2004;6:280-5
3. Drucker DJ. Dipeptidyl peptidase -. inhibition and the treatment of type 2 diabetes: Preclinical biology and mechanisms of action. Diabetes Care 2007;30:1335-43.
4. Charbonnel B, Karasik A, Liu J, Wu M, Meninger G. Effcacy and safety of the Dipeptidyl peptidase -. inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone Diabetes Care 2006;29:2638-43.
5. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Effcacy and safety of the Dipeptidyl peptidase -. inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24 week, multicentre, randomized double blind, placebo-controlled parallel group study. Clin Ther 2006;28:1556-68
6. Gallwitz B. Sitagliptin: Profle of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc) 2007;43:13-25. (Pubitemid 46448834)
7. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, et al Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-88.
8. Brazg R, Xu L, Dall Man C, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase -. inhibitor to metformin on 24-h glycemic control and beta cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:186-93.